Current and Potential Pharmacological Treatment Options for Maintenance Therapy in Opioid-Dependent Individuals
- 1 January 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drugs
- Vol. 72 (2), 217-228
- https://doi.org/10.2165/11597520-000000000-00000
Abstract
Opioid dependence, manifesting as addiction to heroin and pharmaceutical opioids is increasing. Internationally, there are an estimated 15.6 million illicit opioid users. The global economic burden of opioid dependence is profound both in terms of HIV and hepatitis C virus transmission, direct healthcare costs, and indirectly through criminal activity, absenteeism and lost productivity. Opioid agonist medications, such as methadone and buprenorphine, that stabilize neuronal systems and provide narcotic blockade are the most effective treatments. Prolonged provision of these medications, defined as maintenance treatment, typically produces improved outcomes when compared with short-duration tapers and withdrawal. The benefits of opioid agonist maintenance include decreased illicit drug use, improved retention in treatment, decreased HIV risk behaviours and decreased criminal behaviour. While regulations vary by country, these medications are becoming increasingly available internationally, especially in regions experiencing rapid transmission of HIV due to injection drug use. In this review, we describe the rationale for maintenance treatment of opioid dependence, discuss emerging uses of opioid antagonists such as naltrexone and sustained-release formulations of naltrexone and buprenorphine, and provide a description of the experimental therapies.Keywords
This publication has 83 references indexed in Scilit:
- Diagnostic and Statistical Manual of Mental DisordersPsychiatry Research, 2011
- Drug Treatment as HIV Prevention: A Research UpdateJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine‐maintained intravenous heroin abusersAddiction, 2010
- Drug Interactions of Clinical Importance among the Opioids, Methadone and Buprenorphine, and Other Frequently Prescribed Medications: A ReviewThe American Journal on Addictions, 2009
- Home- versus office-based buprenorphine inductions for opioid-dependent patientsJournal of Substance Abuse Treatment, 2009
- Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trialThe British Journal of Psychiatry, 2009
- Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviorsJournal of Substance Abuse Treatment, 2008
- Interaction between buprenorphine and atazanavir or atazanavir/ritonavirDrug and Alcohol Dependence, 2007
- Pharmacokinetics and Subjective Effects of Sublingual Buprenorphine, Alone or in Combination with NaloxoneClinical Pharmacokinetics, 2004
- Alternate-day dosing during buprenorphine treatment of opioid dependenceLife Sciences, 1994